INNSBRUCK, Austria, February 27, 2013 /PRNewswire/ --
Austrian BIOCRATES Life Sciences AG, prime developer of cutting-edge metabolite metabolomics products, is about to launch the next edition of its well-established research kit, AbsoluteIDQ® p150, for use with Thermo Scientific's TSQ Vantage Triple Stage Quadrupole Mass Spectrometer.
BIOCRATES Life Sciences announces the launch of a new edition of its well-established research kit, AbsoluteIDQ® p150. The kit, which has been available for use with AB Sciex and Waters mass spectrometry systems, has now been designed to also run on Thermo Scientific's TSQ Vantage Triple Stage Quadrupole Mass Spectrometer, enabling even more research labs to harness the power of targeted metabolite quantification based on a ready-to-use kit system. Combined with a robust new ion source, second-generation ion optics and hyperbolic quadrupoles, the Thermo Scientific TSQ Vantage delivers the highest sensitivity with the lowest chemical noise.
AbsoluteIDQ p150 provides extensive metabolic information from a single targeted assay, quantifying 158 metabolites using a FIA-MS/MS method. It features the proprietary MetIDQ™ software, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice for researchers looking for a cost-effective solution to measure endogenous metabolites under quality-controlled conditions in their own lab. The AbsoluteIDQ kits by BIOCRATES have been successfully applied in many different areas, including diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research.
BIOCRATES Life Sciences AG is a leading biotechnology company focused on the development of metabolomics products as well as in vitro diagnostics (IVDs) for early disease and progression detection in areas such as nephrology, diabetes, oncology, and endocrinology. Our mass spectrometry-based, standardized metabolomic kits and IVDs provide unprecedented accuracy, precision, and multiplexing potential that will help revolutionize the way personalized medicine is applied in R&D and diagnostics.
SOURCE BIOCRATES Life Sciences AG